Updated on 18 March 2013
In Japan, Daiichi Sankyo also completed a PRASFIT-Elective phase III clinical study that evaluated the
efficacy and safety of prasugrel in elective patients with stable angina and chronic myocardial infarction undergoing PCI. Based on the results of the two studies, Daiichi Sankyo expects to submit a new drug application in Japan in the first half of the Japanese fiscal year 2013 for commercial approval of prasugrel for patients undergoing PCI.
In addition to the above mentioned studies, a Japanese domestic phase III trial for patients with ischemic cerebrovascular disease is on-going. This trial is expected to complete in the Japanese fiscal year 2014.